AZD-2389(AZD-2389) - _专利_临床

概要

基本信息

药物类型

小分子化药

别名

AZD-2389

靶点-

作用机制-

治疗领域-

在研适应症-

非在研适应症-

原研机构

AstraZeneca PLC

在研机构

AstraZeneca PLC

非在研机构-

最高研发阶段临床2期

首次获批日期-

最高研发阶段(中国)-

特殊审评-

登录后查看时间轴

关联

2

项与 AZD-2389 相关的临床试验

NCT06750276

/ Recruiting临床2期

A Phase 2a, Randomised, Single-blind, Placebo-controlled Study to Evaluate the Safety, Tolerability, and Pharmacokinetics and Explore the Pharmacodynamic Effects of AZD2389 in Participants With Liver Fibrosis and Compensated Cirrhosis

The purpose of this study is to measure the safety, tolerability, and the way the body absorbs, distributes, and metabolises AZD2389 as compared to placebo in participants with liver fibrosis and compensated cirrhosis. The study will also examine how the drug acts on the body.

开始日期2024-12-06

申办/合作机构

AstraZeneca PLC

NCT06138795

/ Recruiting临床1期

A Phase I, Randomized, Single-blind, Placebo-controlled Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AZD2389 After Single and Multiple Ascending Doses to Healthy Participants.

This study will assess the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of AZD2389 following single and multiple dose administration (SAD/MAD) to healthy participants.

开始日期2023-11-20

申办/合作机构

AstraZeneca PLC

100 项与 AZD-2389 相关的临床结果

登录后查看更多信息

100 项与 AZD-2389 相关的转化医学

登录后查看更多信息

100 项与 AZD-2389 相关的专利（医药）

登录后查看更多信息

100 项与 AZD-2389 相关的药物交易

登录后查看更多信息